In June 2003 the MHRA announced the change to recommended international non-proprietary names (rINNs) for virtually all medicinal substances which previously had British Approved Names (BANs). the changes are intended to reduce inconsistencies and prevent medication errors which could arise as a result of using different names and bring the UK in line with other EU Member States.

From 30 June 2004 all prescriptions should be written and dispensed using rINNs (with the exception of adrenaline and noradrenaline).